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Abstract
Background: Although the importance of concurrent treatment for multidrug-resistant tuberculosis (MDR-TB) and HIV co-
infection has been increasingly recognized, there have been few studies reporting outcomes of MDR-TB and HIV co-
treatment. We report final outcomes of comprehensive, integrated MDR-TB and HIV treatment in Lesotho and examine
factors associated with death or treatment failure.
Methods: We reviewed clinical charts of all adult patients who initiated MDR-TB treatment in Lesotho between January
2008 and September 2009. We calculated hazard ratios (HR) and used multivariable Cox proportional hazards regression to
identify predictors of poor outcomes.
Results: Of 134 confirmed MDR-TB patients, 83 (62%) were cured or completed treatment, 46 (34%) died, 3 (2%) transferred,
1 (1%) defaulted, and 1 (1%) failed treatment. Treatment outcomes did not differ significantly by HIV status. Among the 94
(70%) patients with HIV co-infection, 53% were already on antiretroviral therapy (ART) before MDR-TB treatment initiation,
and 43% started ART a median of 16 days after the start of the MDR-TB regimen. Among HIV co-infected patients who died,
those who had not started ART before MDR-TB treatment had a shorter median time to death (80 days vs. 138 days,
p=0.065). In multivariable analysis, predictors of increased hazard of failure or death were low and severely low body mass
index (HR 2.75, 95% confidence interval [CI] 1.27–5.93; HR 5.50, 95% CI 2.38–12.69), and a history of working in South Africa
(HR 2.37, 95% CI 1.24–4.52).
Conclusions: Favorable outcomes can be achieved in co-infected patients using a community-based treatment model when
both MDR-TB and HIV disease are treated concurrently and treatment is initiated promptly.
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Introduction
The convergence of the drug-resistant tuberculosis (DR-TB)
and HIV epidemics represents a growing threat to public health.
People living with HIV are particularly susceptible to TB infection
and disease [1–3] and are often exposed to DR-TB while seeking
care at hospitals and outpatient clinics. There have been many
well-documented outbreaks of multidrug-resistant (MDR) TB
among HIV-positive patients in Europe and the US [4–8].
Historically, DR-TB has not been thought to be a significant
problem in African countries, many of which have generalized
HIV epidemics, but most of these countries do not have the
laboratory capacity for drug resistance surveillance [9]. Drug
resistance surveys available from southern Africa suggest that the
proportion of MDR-TB among TB cases in the region has
increased during the past 15 years [9]. In the shocking discovery of
extensively drug-resistant (XDR) TB in KwaZulu-Natal, South
Africa, these patients were found to be almost exclusively HIV-
positive [10].
Very little is known about the optimal treatment of patients with
MDR-TB and HIV co-infection since most studies of MDR-TB
treatment outcomes have been conducted in low HIV prevalence
countries. Compared to first-line TB therapy, treatment for MDR-
TB is lengthier and more complex, with a higher pill burden and
greater risk of adverse effects from drug toxicity. HIV co-infection
further complicates MDR-TB treatment because of the overlap-
ping toxicities of antiretrovirals and second-line TB drugs [11],
lack of knowledge about drug-drug interactions [12], and multiple
potential causes of clinical deterioration during treatment [13,14].
Despite the lack of scientific evidence, experts generally recognize
the importance of an integrated response to HIV and MDR-TB
[9,15–17]. Recently updated World Health Organization (WHO)
guidelines recommend prompt initiation of antiretroviral therapy
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e46943(ART) for all co-infected MDR-TB patients, irrespective of CD4
cell count [18].
HIV-positive MDR-TB patients have been reported to have
higher rates of mortality, treatment failure, and default than HIV-
negative patients [19–23], but many of these studies were
conducted before ART was widely available. A small number
studies reporting outcomes of concurrent ART and DR-TB
treatment have shown that ART improves the prognosis for co-
infected patients [23–25]. We have previously reported early
outcomes of MDR-TB treatment in Lesotho, where the majority
of patients are HIV-positive [26]. Here we report final outcomes of
comprehensive, integrated MDR-TB and HIV treatment in




This study was approved by the Partners HealthCare Human
Research Committee. In the approved protocol, the requirement
for informed consent was waived, since this was a retrospective
study of information previously collected in the course of routine
clinical care.
Setting and Treatment Program
Lesotho, a mountainous country surrounded by the Republic of
South Africa, faces a dual epidemic of TB and HIV. The
estimated TB prevalence is 402 cases per 100,000 population [27],
and the adult HIV prevalence is 24% [28]. Since 2007, the
Ministry of Health and Social Welfare, with support from the non-
governmental organization Partners In Health, has provided free
diagnosis and treatment for patients with MDR-TB.
Patients with suspected MDR-TB who did not have drug
susceptibility testing (DST) results at the time of referral were
classified by risk level according to their treatment history and
clinical, bacteriological, and radiological criteria [26]. High-risk
patients were initiated on a standardized empiric regimen of six
antituberculous drugs–pyrazinamide, kanamycin, levofloxacin,
prothionamide (or ethionamide), cycloserine, and para-aminosa-
licylic acid–while awaiting culture and DST results. With few
exceptions, patients began MDR-TB treatment within one week of
their initial evaluation by clinicians in the national MDR-TB
program.
The Lesotho National Reference TB Laboratory performed
culture and DST for isoniazid, rifampicin, ethambutol, and
streptomycin using a BACTEC MGIT 960 system (Becton-
Dickson, Sparks, Maryland, USA). Specimens for smears and
cultures were routinely collected at the initial evaluation, including
sputum samples, pleural fluid specimens, and lymph node
aspirates. Sputum induction with nebulized saline was used for
patients who were unable to produce sputum at the initial
evaluation.
All patients with unknown HIV status at the start of MDR-TB
treatment were offered HIV counseling and testing. Co-infected
patients who were not yet on ART began ART as soon as they are
tolerating the MDR-TB regimen, regardless of CD4 cell count.
The standard regimen consisted of two nucleoside reverse
transcriptase inhibitors (lamivudine and zidovudine) and one
non-nucleotide reverse transcriptase inhibitor (efavirenz).
The program integrated MDR-TB and HIV care at the
community, clinic, and hospital levels [29]. Patients who were
critically ill at the start of treatment or experienced severe adverse
effects were hospitalized at a specialized inpatient facility in
Maseru, where one clinical team managed HIV and MDR-TB for
co-infected patients. When ready for discharge, a team of
community nurses was responsible for assessing the home
situation, educating the family, and arranging for a trained
community health worker (CHW) to provide twice-daily DOT in
the patient’s home for both antiretrovirals and second-line TB
drugs.
The CHW also accompanied the patient to the clinic monthly
for management of both HIV and MDR-TB at the same visit.
During the monthly visit, patients underwent routine laboratory
monitoring, including sputum smears and cultures, creatinine,
electrolytes, and liver enzymes. CHWs received regular training
on HIV and MDR-TB and close supervision, including surprise
spot visits by the community nurses. The nurses rotated being on
call to receive reports from the CHWs about any severe side effects
or clinical deterioration experienced by the patients. CHWs were
reimbursed for all costs incurred and compensated with perfor-
mance-based payment that was dependent on their monthly
evaluation.
The Lesotho MDR-TB program emphasized a holistic
approach to patient care that included social, psychological, and
economic support. Patients were not charged user fees in
accordance with National TB Program guidelines. All patients
received a food package and reimbursement for travel expenses
related to treatment. CHWs and community nurses were trained
in psychological support, and clinicians made every effort to
provide humane and decent care without stigmatization.
Patient Selection
In September 2011, we retrospectively reviewed the clinical
charts of patients in the Lesotho national MDR-TB program who
initiated second-line TB treatment between January 1, 2008 and
September 29, 2009. Patients were included in the analysis if they
had DST-confirmed MDR-TB (resistance to both isoniazid and
rifampicin) and were 15 years of age or older. Patients were
referred from all ten districts in Lesotho. Approximately one-third
of patients were from Maseru district, the district surrounding the
capital, and the remaining patients were distributed among the
other nine districts.
Statistical Analysis
We compared baseline characteristics between HIV-positive
and HIV-negative patients using the Fisher’s exact test for
dichotomous and categorical variables and the Wilcoxon rank-
sum test for continuous variables. Standard definitions for
retrospective MDR-TB analyses were used to determine final
treatment outcomes [30]. Smear and culture results were
considered baseline if they were from sputum samples taken
within one month before or one week after initiation of MDR-TB
treatment.
Cox proportional hazards modeling was used to assess potential
risk factors for failure or death. We evaluated the proportional
hazards assumption using the Kolmogorov-type supremum test.
Patients who transferred out, defaulted, or completed treatment
were censored at the date of their last visit. We imputed missing
data using multiple imputation methods relying on all other
variables. We used bivariable and multivariable analysis with each
covariate, HIV status, and the interaction terms to identify
confounding and effect modification. All variables examined in the
bivariable analysis were considered as candidates for the
multivariable model; interaction terms between baseline variables
and HIV status that were significant at the p,0.1 level were also
considered as candidates. We used a backward elimination process
to build the final multivariable model. HIV status was retained in
the final multivariable model, as it was the primary variable of
MDR-TB Treatment Outcomes in Lesotho
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were significant at the p,0.1 level in the multivariable model or if
they changed the effect estimate for HIV status by more than 15%.
SAS, version 9.2 (SAS Institute, Cary, North Carolina) was used
for all analyses.
Results
Between January 1, 2008 and September 29, 2009, 259 adult
patients were initiated on treatment for confirmed or suspected
MDR-TB. Seventy-seven patients were excluded from further
analysis because they did not have DST results, and 48 patients
were excluded from further analysis because DST revealed that
they had pan-susceptible (n=28), mono-resistant (n=15), or poly-
resistant, non-MDR (n=5) strains. The remaining 134 patients
with DST-confirmed MDR-TB were included in the study.
At baseline, 57 patients (42.5%) had low body mass index (BMI)
(,18.5 kg/m
2), and 19 (15.8%) had severely low BMI (,16 kg/
m
2). Thirty-five patients (26.2%) had been treated three or more
times for TB, and 18 (13.4%) reported a history of treatment with
second-line TB drugs. Most patients had severe radiographic
findings: 118 patients (91.5%) had bilateral disease and 96 (74.4%)
had cavitary disease or fibrosis. Table 1 presents the baseline
clinical and demographic characteristics for the patients in this
cohort by HIV status.
Ninety-four (70.2%) patients were co-infected with HIV. At the
start of the MDR-TB regimen, 50 (53.2%) of these patients were
already on ART and had been on ART a median of 197 days
(interquartile range [IQR], 91–511). Forty patients started ART
after MDR-TB treatment was initiated, a median of 16 days (IQR,
6.5–31) later. Only four out of 94 patients never began ART, three
of whom died within three months of starting MDR-TB
treatment.
Among HIV co-infected patients who were tested within six
months before or after initiation of MDR-TB treatment, median
CD4 cell count was 220 cells/mm
3 (IQR, 75–323). Of the 44
patients who were not on ART at the time of MDR-TB initiation,
33 had CD4 cell testing within six months before or after MDR-
TB initiation. Of these, 9 patients (27.3%) had CD4 cell counts
$350 cells/mm
3, 7 (21.2%) between 200 and 349 cells/mm
3,1 1
(33.3%) between 50 and 199 cells/mm
3, and 6 (18.2%) ,50 cells/
mm
3.
Patients received MDR-TB treatment for a median of 22.9
months (IQR, 21.6–24.0) (Table 2). Treatment regimens were
largely uniform–100% patients received a parenteral agent, 100%
fluoroquinolone, 99.3% prothionamide (or ethionamide), 98.5%
cycloserine, 95.5% pyrazinamide, 96.3% para-aminosalicylic acid,
2.3% terizidone, and 1.5% ethambutol. Kanamycin was the most
commonly prescribed parenteral agent: 68.7% received kanamy-
cin, 22.4% capreomycin, and 9.0% amikacin. Ofloxacin was the
most commonly prescribed fluoroquinolone: 47.0% received
ofloxacin, 42.5% levofloxacin, and 10.5% moxifloxacin. Forty
patients (29.9%) were hospitalized at MDR-TB treatment
initiation for a median of 34 days (IQR, 22–70), and 77 patients
(57.7%) were hospitalized at some point during MDR-TB
treatment.
The treatment success rate was 61.9%: 71 patients (53.0%) were
cured, 12 (9.0%) completed treatment, 46 (34.3%) died, 3 (2.2%)
transferred, 1 (0.8%) defaulted, and 1 (0.8%) failed treatment.
Treatment outcomes did not differ significantly by HIV status
(Table 2). Among patients with positive baseline cultures who
converted, median time to culture conversion was 64.5 days (IQR,
38.5–95.0). Of those who died, 19 (41.3%) died within three
months of treatment initiation, and 30 (65.2%) died within six
months.
For those who were HIV co-infected, there was no association
between hazard of death or failure and either CD4 cell count
,200 cells/mm
3 (hazard ratio [HR] 0.62, 95% confidence
interval [CI] 0.23–1.68) or ART initiation prior to the start of
MDR-TB treatment (HR 0.65, 95% CI 0.31–1.35). Although
patients who started ART prior to MDR-TB treatment had a
similar mortality rate compared with HIV co-infected patients
who had not started ART before MDR-TB treatment (28% vs
34%, p=0.655), those who were not already on ART had a
significantly shorter median time to death (80 days vs. 138 days,
p=0.065).
In the final multivariable model, low or severely low BMI (HR
2.75, 95% CI 1.27–5.93; HR 5.50, 95% CI 2.38–12.69,
respectively), and a history of working in South Africa (2.37,
95% CI 1.24–4.52) were significantly associated with greater
hazard of death or failure (Table 3). HIV status was not a
significant predictor of time to poor outcome in any of the models
examined.
Discussion
Despite the poor baseline clinical status of patients in this
cohort, including a high rate of HIV co-infection, low BMI, and
extensive lung damage, the treatment success rate was comparable
to what has been reported in settings of low HIV prevalence [31–
33]. Our findings demonstrate that good MDR-TB outcomes in
the context of HIV are achievable using a community-based
model. The traditional model of MDR-TB treatment in this region
of the world has been hospital-based care, at least during the
intensive phase of treatment, with the rationale that this model
improves adherence, limits community transmission, and allows
close monitoring, particularly for HIV co-infected patients who
present more challenges for clinical management [34]. We largely
attribute the success of this community-based program in Lesotho
to the integration of MDR-TB and HIV care, empiric second-line
TB treatment, and early ART initiation.
In Lesotho, CHWs were trained to administer both antiretro-
virals and second-line TB drugs. A team of community nurses also
provided strong communication between the CHWs and the clinic
and hospital staff. CHWs were trained to recognize signs and
symptoms of adverse effects requiring urgent referral to the clinic.
Finally, patients were provided with food packages, transportation
reimbursement, and other types of psychosocial support. These
critical elements of community-based care for MDR-TB helped
patients to transition successfully between the hospital and the
community and finish the long treatment required for MDR-TB in
their homes [29].
As a result, there was a very low rate of default (,1%) in this
study population, in comparison to default rates exceeding 20% in
programs in South Africa that have used inpatient care during the
intensive phase and outpatient care without DOT during the
continuation phase [19–21]. In other studies of MDR-TB
treatment outcomes, high default rates may mask the true death
or failure rate, since patients often default if they fail to improve
clinically. Surprisingly, there was no significant difference in
hazard of death or failure by HIV status in this cohort in Lesotho.
Previous studies have reported high mortality rates among MDR-
TB/HIV co-infected patients [19–23]. However, these studies
either were undertaken before ART was available [20–22] or
examined outcomes of a study population in which few patients
were receiving ART [19].
MDR-TB Treatment Outcomes in Lesotho
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ART during MDR-TB treatment. Lesotho has made great strides
in scaling up ART in recent years. Although there continue to be
gaps in access, many more TB/HIV co-infected patients are
diagnosed with HIV and appropriately started on ART compared
to the early 2000’s. Of the 94 HIV-positive MDR-TB patients in
this cohort, more than half had already been started on ART,
usually during a previous course of TB treatment.
Recent WHO guidelines recommend that ART should be
initiated 2–8 weeks after the start of MDR-TB treatment
irrespective of CD4 cell count [18]. Dheda et al. showed that
HIV-positive XDR-TB patients who never received ART had a
higher mortality than those who were already on ART [25].
Palacios et al. found that ART confers a protective effect for HIV
co-infected MDR-TB patients, but the median time from the start
of MDR-TB treatment to ART initiation exceeded five months
[23]. In this cohort in Lesotho, nearly all HIV-positive patients not
yet on ART were initiated on ART within several weeks of starting
MDR-TB treatment. Nevertheless, the time to death in HIV-
positive patients who were not already on ART prior to MDR-TB
treatment was significantly shorter compared to HIV-positive
patients who were already on ART. This indicates that early
Table 1. Baseline demographic and clinical characteristics of MDR-TB patients, by HIV status.
a





Age (years) 43 (27.5–58.5) 39.5 (33–46) 0.3031
BMI (kg/m
2)
d Severely low (,16) 7 (20.0) 12 (14.1) 0.4118
Low (16 to ,18.5) 13 (37.1) 25 (29.4)
Normal ($18.5) 15 (42.9) 48 (56.5)
Hemoglobin (g/dL) 12.1 (10.9–13.4) 11.1 (9.7–12.7) 0.0860
Albumin (g/L) 32.0 (27.5–36.0) 31.0 (27.0–37.0) 0.8366
Resting respiratory rate (breaths/min) 24 (23–28) 26 (24–28) 0.8292
Number of previous TB treatment regimens None 1 (2.5) 4 (4.3) 0.5198
One 10 (25.0) 33 (35.1)
Two 19 (47.5) 32 (34.0)
Three or more 10 (25.0) 25 (26.6)
Time since first TB diagnosis (months) 29.9 (8.8–82.1) 19.0 (8.2–50.8) 0.2911
Sputum smear Positive 7 (17.5) 8 (8.5) 0.2220
Negative 22 (55.0) 50 (53.2)
Not available 11 (27.5) 36 (38.3)
Number of drugs to which isolate was resistant 2 or 3 14 (35.0) 42 (44.7) 0.3420
$4 26 (65.0) 52 (55.3)
Previous exposure to second-line TB drugs Yes 2 (5.0) 16 (17.0) 0.0943
No 38 (95.0) 78 (83.0)
Fibrotic or cavitary lesions on chest radiograph Yes 31 (79.5) 65 (72.2) 0.5106
No 8 (20.5) 25 (27.8)
Bilateral disease on chest radiograph Yes 37 (94.9) 81 (90.0) 0.5027
No 2 (5.1) 9 (10.0)
Extrapulmonary TB Yes 2 (5.0) 5 (5.3) 1.0000
No 38 (95.0) 89 (94.7)
Hospitalized at treatment initiation Yes 10 (25.0) 30 (31.9) 0.5369
No 30 (75.0) 64 (68.1)
Sex Male 25 (62.5) 54 (57.5) 0.7017
Female 15 (37.5) 40 (42.6)
Worked in South Africa Yes 22 (56.4) 45 (48.9) 0.4515
No 17 (43.6) 47 (51.1)
Worked in South Africa as a miner Yes 14 (35.9) 28 (31.5) 0.6842
No 25 (64.1) 61 (68.5)
Note: BMI: body mass index.
aTable values are median (IQR) for continuous variables and n (column %) for categorical variables.
bNumbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding.
cP-value is for Wilcoxon rank sum test (continuous variables) or Fisher’s exact test (categorical variables).
dFor patients under 20 years of age, severely low BMI was defined as ,2 3 standard deviations, low BMI was defined as ,2 2 standard deviations, according to World
Health Organization BMI-for-age charts for 5–19 years, 2–5 years.
doi:10.1371/journal.pone.0046943.t001
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immunosuppressed may take several months to show a benefit
from ART.
Another reason for the improved outcomes among HIV-
positive patients compared to HIV-negative patients may have
been the empirical use of second-line TB drugs, which interna-
tional guidelines recommend for patients with a high likelihood of
MDR-TB [35–37]. If culture-based DST methods are used, as was
the case for Lesotho during the study period, it may take months
for DST results to become available. Studies from KwaZulu-
Natal, South Africa have found that when DR-TB/HIV co-
infected patients were treated with standard first-line TB therapy
while awaiting DST results, many did not survive long enough to
initiate appropriate treatment [19,34]. While the increasing access
to rapid molecular methods of DST may make empiric MDR-TB
therapy less necessary in the future, the findings from these studies
underscore the need for rapid diagnosis of DR-TB and early
initiation of second-line TB drugs in settings with high HIV
prevalence.
Finally, survival bias or referral bias may have affected the
baseline characteristics and outcomes of HIV co-infected patients
in this cohort. Unmeasured factors that affected the DR-TB/HIV
co-infected patients’ ability to survive until referral and evaluation
for MDR-TB might lessen the effect of HIV on MDR-TB
treatment outcomes. Since many of the HIV co-infected patients
were already in ART or pre-ART care at the time they were
referred for evaluation of MDR-TB, they may have been
identified and referred at an earlier stage in the progression of
their TB disease compared to patients without HIV co-infection,
although they did not differ significantly on measured signs of
severe, protracted disease (low BMI, bilateral disease, fibrotic or
cavitary disease, or elevated respiratory rate).
Our multivariable analysis revealed several other factors
associated with increased risk of poor outcomes. First, similar to
previous studies [20,31,38], we found a strong, independent
association between low BMI at baseline and increased risk of
death or failure. Because low BMI is a sign of severe TB or
HIV disease, the strong association between low BMI and
greater hazard of death or failure is not surprising and
underscores the importance of early initiation of appropriate
therapy. Second, a history of working in South Africa was also
a significant, independent predictor of greater hazard of death
or failure. A significant proportion of the male population in
Lesotho–an estimated 50,000 men annually–work in South
African mines, and the occupational hazards and social context
of mining puts them at greater risk for acquiring TB [39,40].
Additionally, living in South Africa may affect patients’ health
care access, health care seeking, and treatment history prior to
referral for suspected MDR-TB, which in turn may affect
unmeasured baseline clinical characteristics that have implica-
tions for MDR-TB treatment outcomes.
This study used data collected during the course of routine
clinical practice. Some patients were missing DST results, because
of negative or contaminated baseline cultures resulting from issues
at the national laboratory, and were excluded from the study. The
Lesotho National Reference TB Laboratory did not have the
capacity to perform DST for second-line antituberculous drugs, so
the prevalence of XDR-TB among the patients in this cohort is
unknown. Given the proximity to KwaZulu-Natal, a proportion of
the deaths in this cohort may have been attributable to XDR-TB
[10]. Another limitation is that some patient charts were missing
additional baseline data, notably height (10%), albumin (22%) and
hemoglobin (6%). We imputed this data, assuming the data are
missing at random, which is plausible but untestable with the data.
The general conclusions did not change when we restricted to a
complete analysis.
The Lesotho MDR-TB treatment model is comprehensive. It
includes strong links between community-based, clinic and
inpatient care; DOT throughout treatment; empiric use of
second-line TB drugs while awaiting DST results; and concurrent
ART and MDR-TB treatment for more than 95% of co-infected
patients. The treatment success rate for this program in a high
HIV-prevalence setting is comparable to those reported from
settings of low HIV prevalence. More research on the clinical
management and outcomes of MDR-TB/HIV co-infected
patients treated concurrently for MDR-TB and HIV disease is







Final outcomes Cured 17 (42.5) 54 (57.5) 0.3613
Treatment completed 4 (10.0) 8 (8.5)
Died 17 (42.5) 29 (30.9)
Defaulted 1 (2.5) 0 (0.0)
Failed 0 (0.0) 1 (1.1)
Transferred 1 (2.5) 2 (2.1)
Treatment duration (months) 22.4 (21.6–24.0) 22.9 (21.8–23.9) 0.8838
Time on parenteral agent (months)
d 10.2 (9.4–11.3) 10.5 (0.3–11.4) 0.6370
Time to culture conversion (days) (N=84)
e 59 (49–89) 66 (38–98) 0.6398
Time to smear conversion (days) (N=79)
e 48 (23–63) 66.5 (31–97) 0.0571
Time to death (days) 136 (86–340) 110 (66–208) 0.4169
aTable values are median (IQR) for continuous variables and n (column %) for categorical variables.
bNumbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding.
cP-value is for Wilcoxon rank sum test (continuous variables) or Fisher’s exact test (categorical variables).
dCalculated among those who completed the intensive phase of treatment.
eCalculated among those who had positive results at baseline (within one month before or one week after initiation of MDR-TB treatment).
doi:10.1371/journal.pone.0046943.t002
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PLOS ONE | www.plosone.org 5 October 2012 | Volume 7 | Issue 10 | e46943needed. Future studies should evaluate the effect of timing of ART
after initiation of MDR-TB treatment on treatment outcomes,
frequency and severity of adverse reactions, and incidence of
immune reconstitution inflammatory syndrome. Nevertheless, the
findings from Lesotho suggest that favorable outcomes can be
achieved in co-infected patients when both MDR-TB and HIV
disease are treated concurrently and treatment is initiated
promptly.
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